Evaluate the Safety and Explore the Efficacy of DWP712 With Moderate to Severe Glabellar Lines
Double-blind, Randomized, Parallel Design, Active-controlled Phase 1 Clinical Trial to Evaluate the Efficacy and Safety of DWP712 and Botox® in Adult Patients in Need of Moderate to Severe Glabellar Lines
Sponsor: Daewoong Pharmaceutical Co. LTD.
Listed as NCT06212960, this PHASE1 trial focuses on Glabellar Lines and remains completed. Sponsored by Daewoong Pharmaceutical Co. LTD., it has been updated 5 times since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
5 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
May 2024 — Jul 2024 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Feb 2024 — May 2024 [monthly]
Recruiting PHASE1
First recorded
Nov 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Daewoong Pharmaceutical Co. LTD.
For direct contact, visit the study record on ClinicalTrials.gov .